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Background: There are over 130 different types of tumors in the central nervous system that 
include astrocytoma, glioblastoma, oligodendroglioma, meningioma, and schwannoma. From them, 
glioblastoma is considered the most common lethal primary brain tumor in adults.
Objective: To create an overview of different angiogenic pathways of the glioblastoma. 
Material and Method: The 277 histopathologically confirmed consecutive primary brain 
tumors diagnosed at Department of Pathology of Emergency County Hospital of Tirgu-Mures, Romania, 
during 2012-2013, were retrospectively checked to see the incidence and immunohistochemical (IHC) 
particularities of glioblastoma. The immunostains were performed in 35 randomly selected 
glioblastomas, using the angiogenesis-related antibodies Vascular Endothelial Growth Factor (VEGF-
A), COX-2, Maspin, and Epidermal Growth Factor Receptor (EGFR). 
Results: From the 277 tumor cases, 62 (22.38%) were glioblastomas. Most of them (85.48%, 
n=53) were diagnosed in patients over 40, with a male:female ratio of 1.4:1. From the 35 cases used for 
IHC examinations, only 6 were marked by VEGF (17.14%), the other 29 (82.86%) being VEGF 
negative. No one of the cases showed maspin posivity. The rate of positivity for EGFR and COX-2 was 
37.14% (n=13) and 60% (n=21), respectively. All of the 13 EGFR positive cases displayed COX-2
positivity and did not showed VEGF expression.
Conclusions: In glioblastoma cells, the angiogenesis is rather mediated by COX-2 than VEGF 
or maspin. In patients with VEGF negative glioblasomas, the anti-EGFR drugs could be succesfully 
used. The effect of anti-EGFR drugs can be improved when combined with anti-COX-2 agents.
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Introduction. Cardiovascular complications of diabetes mellitus have a high incidence with 
repercussions affecting the patients’ quality of life. Beta blockers have an important role in treating those 
complications. However, their use may be Associated with some harmful effects. So, the goal of this 
paper is to find out possible ways of safe beta blockers’ use in treatment of diabetes mellitus.
Materials and methods. In order to achieve this goal, there was performed a profound analysis 
of bibliographical and reference sources referring to beta blockers use in diabetes treatment. 
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Discussion results. Diabetes mellitus ia a relative contraindication for beta blocker therapy, 
because it may block the glycogenolysis and tisular glucose mobilization, thus impairing the recovery 
from hypoglycemic crisis or hiding its symptoms, may reduce the insulin secretion and raise TAG, HDL, 
rs they 
may cause a weight gain of 1-2 kgs. On the other hand, diabetes has multiple complications like arterial 
hypertension, ischemic heart diseases and cardiac insufficiency- those that are proved to be treated well 
may reconsider the use of beta blockers that can treat those 
efficient in cardiovascular problems than converting enzyme inhibitors in diabetic patients. Comparing 
shows almost the same efficiency rate.
Conclusion. Beta blockers, if chosen accurately may serve as an efficient way of treatment the 
diabat -
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Introduction: Urinary tract infections are the most common bacterial infections in women and 
account for significant morbidity and health care costs. A limited and predictable spectrum of organisms 
cause urinary tract infections in young, otherwise healthy females. Among both outpatients and 
inpatients, Escherichia coli is the primary urinary tract pathogen, accounting for 75 to 90% of 
uncomplicated urinary tract infection isolates. Staphylococcus saprophyticus, Klebsiella spp., Proteus 
spp., Enterococcus spp., and Enterobacter spp. are pathogens less commonly isolated from outpatients.
Aim: The present study was conducted to determine regional, and institutional in vitro 
susceptibilities for ampicillin, ciprofloxacin, nitrofurantoin, and SXT among urine isolates of E. coli 
from female outpatients from Urology Department of Emergency Hospital,Targu Mures from Romania.
In addition, the rate of change in susceptibilities to these four commonly tested antimicrobial agents over 
3 years, from 2012 to 2014, was also determined.
Materials and Methods: We retrospectively reviewed 272 patients with a urinary tract infection 
with Escherichia Coli starting in 01.01.2012 to 31.12.2014 from Urology Departament by Emergency 
County Hospital Targu Mures. The susceptibility testing results(by Kirby-Bauer technique) included in 
the analysis were restricted to urine isolate of E. coli submitted per calendar year by female outpatients 
of all ages. We will provide data about the evolution under this treatment. All statistical analisys were 
performed using GraphPad Prism 6.0.
Results: Ampicillin, ciprofloxacin, nitrofurantoin, and SXT susceptibilities for urine isolates of 
E. coli from female outpatients during the years 2012 through 2014: for the Ampicillin (susceptibility 
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